Drug Delivery Business

Dexcom exec highlights benefits of CGM for type 2 diabetes, continued innovation

At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people with diabetes.

Dexcom gives sneak preview of CGM technologies’ long-term health benefits for diabetics

Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and ...
The Verge

Dexcom adds AI reports to its OTC glucose monitor.

Dexcom’s Stelo continuous glucose monitor (CGM) for those with Type 2 diabetes is starting to use generative AI to write weekly reports with “more personalized tips, recommendations, and education ...
Drug Delivery Business

Dexcom highlights breakthrough type 2 diabetes outcomes at ATTD

Dexcom (Nasdaq:DXCM) today announced its plans to share new data supporting its diabetes management technology at ATTD 2026.